Ligand Pharmaceuticals
Prezzo: 255.54Società e modello di business
Ligand Pharmaceuticals is a biotechnology company focused on developing and commercializing technologies that enhance drug discovery and development. Its core products include a range of proprietary technologies and partnered programs that facilitate the creation of therapeutics across various disease areas. Major business segments include royalty revenue from partnered products and licensing agreements. The primary revenue sources stem from collaborations with pharmaceutical companies and royalties from sales of drugs utilizing Ligand's technologies.
Profilo di investimento
The investment profile of Ligand Pharmaceuticals is more aligned with value investors, given its current market position and revenue trends. The stock may appeal to those seeking potential long-term appreciation, although recent performance indicates challenges. Investors should consider the company's volatility and risk factors when evaluating their investment horizon.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 7.84 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -13.3% ↓
- Sorpresa EPS
- -11.4% peggio del previsto
- Volatilità 20g
- 1.8% stabile
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-05-24 02:44 | Vendi | Mantieni | Weak fundamentals and high risk limit upside potential. |
| 2026-05-16 02:46 | Mantieni | Vendi | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 15:20 | — | Mantieni | Weak fundamentals and negative momentum raise concerns. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-04-30 10:09 | H.C. Wainwright | Target alzato | 243 → 289 | 224.86 |
| 2026-04-28 11:36 | RBC Capital | Target alzato | 235 → 252 | 241.79 |
| 2026-04-27 18:05 | Stifel Nicolaus | Target alzato | 230 → 255 | 241.79 |
Ancora nulla